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Research into the role of metals in Alzheimer’s disease
(AD) has rapidly advanced over the past two decades. Early
studies described controversial links between trace metals
and dementia. More recently, this concept has developed
further with the understanding that a range of biometals and
environmental metal toxins are likely to have a central role in
determining the onset, progression, and clinical outcomes of
AD and other forms of neurodegeneration. Key studies were
instigated in the early 1990s by Ashley Bush and colleagues,
demonstrating that metals such as zinc and copper were
criticalinamyloidbeta(Aβ)aggregationand(neuro)to xicity .
Subsequent studies on metals in AD have opened up vast
areas of research including the role for metals in amyloid
precursor protein (AβPP) metabolism and processing, Aβ
cleavage and degradation, synaptic Aβ-metal interactions,
and neuroprotection associated with modulation of metal
homeostasis.
In this issue we have provided a broad insight into some
of these exciting areas of research, and the conclusion seems
to be that a far greater level of understanding is still needed
to allow development of treatments to halt the progression
of AD. Tabner et al. and Kawahara and Kato-Negishi have
described how interaction of Aβ with metals such as copper
and iron is associated with (neuro)toxic action of small,
soluble Aβ oligomers, likely mediated through generation of
reactive oxygen species (ROS) and in particular, the highly
reactive hydroxyl radical. In a related article, Yang et al. have
provided valuable research into the importance of helical
sheet formation in ROS generation associated with copper
interactions. While metal interactions with Aβ are clearly
critical for its (neuro)toxic processes, metals also have a key
role in generation of Aβ. Ho et al. have described research
demonstrating that calcium and magnesium are required for
γ-secretase activity, which is the ﬁnal cleavage step in Aβ
generation. An important, but still undeﬁned role for iron
in AD is supported by the study described by Squitti et al.
where they associated ceruloplasmin/transferrin ratios and
transferrin saturation with cognitive decline and increased
oxidative stress in AD. A broad review by Salvador et al.
brings together an interesting overview of how neurons
handleironandhowirondysregulationmayleadtoneuronal
degeneration in AD. Likewise, zinc has a clear and important
role in AD. It is involved in many processes central to the
disease, including AβPP and Aβ processing and degradation,
and zinc is released into the synapse where it can modulate
neurotoxic action of Aβ and glutamate neurotoxicity, two
factors that are closely associated with AD (Watt et al. and
Takeda).
B. Weiss takes us in a diﬀerent direction, reviewing the
importance of exposure to environmental metals during
development and their possible association with AD later
in life. Such interactions may have key modulating roles in
neurodegeneration and have not been adequately investi-
gated. Of course, the aim of understanding metals in AD, like
any AD research, is primarily to form the basis of potential
therapeutic treatments. In relation to this, El Ghazi et al.
describe interesting interactions between metallothionein
and proteins associated with transport, signaling and chap-
eroning, highlighting the complexity of metal interactions2 International Journal of Alzheimer’s Disease
with AD, both direct (Aβ-metal) and indirect, through met-
allothionein. Amadoruge and Barnham review the potential
modulation of membrane receptor function by metals. In
addition, Srinivasan et al. report on the potential use of
melatonin to provide neuroprotective action early in the
course of AD. Finally, the paper by Braymer et al. highlights
the importance of developing novel tools to investigate the
role of metals in AD and has described the generation of
moleculesthatmaytargetAβ andmetalssimultaneously.Itis
hoped that the research and reviews described here will help
to update the AD research community on the state of play in
regards to metals in AD and oﬀer insights into where future
research should be directed.
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